These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32482412)

  • 21. Papulonecrotic tuberculid after Bacillus Calmette-Guérin (BCG) vaccination with lung infiltration that mimics disseminated BCG infection.
    Miyamura T; Egashira S; Yoshino Y; Sawatari M; Nishihara T; Ihn H
    J Dermatol; 2019 Aug; 46(8):e267-e268. PubMed ID: 30811058
    [No Abstract]   [Full Text] [Related]  

  • 22. Molecular microbiological investigation of post-vaccination bacille Calmette-Guérin infection in Iranian patients.
    Shojaei H; Rahimi-Hajiabadi H; Heidarieh P; Hashemi-Shahraki A; Emadoleslami M; Ataei B; Naser AD
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1497-503, i. PubMed ID: 22008763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of the Polish BCG-10 Vaccine During a Period of BCG Vaccine Shortage: An Australian Experience.
    Wong NX; Buttery J; McMinn A; Azhar Z; Crawford NW
    Pediatr Infect Dis J; 2020 Jun; 39(6):e66-e68. PubMed ID: 32150004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent Bacillus Calmette-Guerin Reaction: A Potential Clue to Underlying Immune Deficiency.
    Khalsa A; Rubin AI; Jen M
    Pediatr Dermatol; 2015; 32(5):e215-6. PubMed ID: 26059661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycobacterium bovis (Bacille Calmette-Guérin) bacteremia in immunocompetent neonates following vaccination.
    Thamthitiwat S; Marin N; Baggett HC; Peruski LF; Kiatkulwiwat W; Panumatrasmee V; Varma JK; Nateniyom S; Akarasewi P; Maloney SA
    Vaccine; 2011 Feb; 29(9):1727-30. PubMed ID: 21215347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary immunodeficiency diseases in a tuberculosis endemic region: challenges and opportunities.
    Glanzmann B; Uren C; de Villiers N; van Coller A; Glashoff RH; Urban M; Hoal EG; Esser MM; Möller M; Kinnear CJ
    Genes Immun; 2019 Jul; 20(6):447-454. PubMed ID: 30185814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [BCG vaccine administration schedule and primary immunodeficiencies: Is it time for a change?].
    Sotomayor F C; Palma B J
    Rev Chil Pediatr; 2019 Dec; 90(6):668-674. PubMed ID: 32186591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Primary tubercular infection and BCG vaccination].
    Lindgren I
    Duodecim; 1988; 104(7):554-6. PubMed ID: 3049026
    [No Abstract]   [Full Text] [Related]  

  • 29. A family history of serious complications due to BCG vaccination is a tool for the early diagnosis of severe primary immunodeficiency.
    Roxo-Junior P; Silva J; Andrea M; Oliveira L; Ramalho F; Bezerra T; Nunes AA
    Ital J Pediatr; 2013 Sep; 39():54. PubMed ID: 24016734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [When will the new tuberculosis vaccine appear?].
    Koroliuk AM; Zazimko LA; Petrovskiĭ SV
    Zh Mikrobiol Epidemiol Immunobiol; 2015; (1):86-94. PubMed ID: 25842959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination.
    Lin MY; Geluk A; Smith SG; Stewart AL; Friggen AH; Franken KL; Verduyn MJ; van Meijgaarden KE; Voskuil MI; Dockrell HM; Huygen K; Ottenhoff TH; Klein MR
    Infect Immun; 2007 Jul; 75(7):3523-30. PubMed ID: 17502400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The capacity of Mycobacterium tuberculosis complex species and M. bovis BCG substrains specific identification - implications for optimized PCR-based diagnostics in adverse events following vaccination suspected cases.
    Krysztopa-Grzybowska K; Brzezińska S; Augustynowicz-Kopeć E; Zwolska Z; Augustynowicz E; Lutyńska A
    Pol J Microbiol; 2012; 61(4):299-303. PubMed ID: 23484413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations.
    Basaraba RJ; Izzo AA; Brandt L; Orme IM
    Vaccine; 2006 Jan; 24(3):280-6. PubMed ID: 16153758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case with severe combined immunodeficiency diagnosed with disseminated BCG infection by detecting specific RD gene deletion].
    Akaihata M; Hashimoto K; Kawasaki Y; Hosoya M; Mori S; Suzutani T
    Kansenshogaku Zasshi; 2011 Mar; 85(2):176-9. PubMed ID: 21560422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rethinking newborn screening for severe combined immunodeficiency: Lessons from an international partnership for patients with primary immunodeficiencies in Pakistan.
    Wallace JG; Tipu HN; Stafstrom K; Alosaimi MF; Massaad MJ; Bainter W; Geha RS; Chou J
    Clin Immunol; 2019 May; 202():29-32. PubMed ID: 30858051
    [No Abstract]   [Full Text] [Related]  

  • 36. Cutaneous complication after BCG vaccination: case report and review of the literature.
    Keijsers RR; Bovenschen HJ; Seyger MM
    J Dermatolog Treat; 2011 Dec; 22(6):315-8. PubMed ID: 20964574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails.
    Verreck FAW; Tchilian EZ; Vervenne RAW; Sombroek CC; Kondova I; Eissen OA; Sommandas V; van der Werff NM; Verschoor E; Braskamp G; Bakker J; Langermans JAM; Heidt PJ; Ottenhoff THM; van Kralingen KW; Thomas AW; Beverley PCL; Kocken CHM
    Tuberculosis (Edinb); 2017 May; 104():46-57. PubMed ID: 28454649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
    Nemes E; Geldenhuys H; Rozot V; Rutkowski KT; Ratangee F; Bilek N; Mabwe S; Makhethe L; Erasmus M; Toefy A; Mulenga H; Hanekom WA; Self SG; Bekker LG; Ryall R; Gurunathan S; DiazGranados CA; Andersen P; Kromann I; Evans T; Ellis RD; Landry B; Hokey DA; Hopkins R; Ginsberg AM; Scriba TJ; Hatherill M;
    N Engl J Med; 2018 Jul; 379(2):138-149. PubMed ID: 29996082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety.
    Chen JM; Islam ST; Ren H; Liu J
    Vaccine; 2007 Nov; 25(48):8114-22. PubMed ID: 17954004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial.
    Pereira SM; Barreto ML; Pilger D; Cruz AA; Sant'Anna C; Hijjar MA; Ichihara MY; Santos AC; Genser B; Rodrigues LC
    Lancet Infect Dis; 2012 Apr; 12(4):300-6. PubMed ID: 22071248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.